Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy

AIDS

Volumn 15, Issue 12, 2001, Pages 1579-1581

  Antinori, Andrea ^a   Baldini, Francesco ^b   Girardi, Enrico ^a   Cingolani, Antonella ^b   Zaccarelli, Mauro ^a   Di Giambenedetto, Simona ^b   Barracchini, Annalisa ^a   De Longis, Patrizio ^a   Murri, Rita ^b   Tozzi, Valerio ^a   Ammassari, Adriana ^b   Rizzo, Maria Gabriella ^b   Ippolito, Giuseppe ^a   De Luca, Andrea ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; DIDANOSINE; GLUCOCORTICOID; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PREDNISONE; STAVUDINE;

ADULT; ALLERGY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROPHYLAXIS; RASH; RISK FACTOR; SEX; STEROID THERAPY; VIRUS LOAD;

ADULT; ANTI-ALLERGIC AGENTS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SEX CHARACTERISTICS;

EID: 0035903010     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200108170-00018     Document Type: Article

References (13)

1. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
2. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash
3. A multi-center, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor (PI) by nevirapine in HAART-experienced patients suffering lipodystrophy (LD)
4. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids
5. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
6. The effects of a short course of prednisone on the incidence of rash associated with nevirapine
7. Efficacy of a short term prednisone regimen in nevirapine associated rash prevention: A double-blind placebo-controlled clinical trial. Results of the GESIDA 09/99 study
8. Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction
9. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses
10. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus
11. Gender differences in nevirapine rash
12. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients